NZM2:ETR
Novozymes A/S
€ ५८.००
०.००%
(०.००) 1D
अक्टोबर ९, १७:३५:३० GMT+२ · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for NZM2...
Open
€ ५७.६४
High
€ ५८.१०
Low
€ ५७.६४
Mkt. cap
१.८० खरब
Avg. vol.
१२०.००
Volume
५.००
52-wk high
€ ६१.९६
52-wk low
€ ४६.७४
No. of employees
११ हजार
Open
€ ५७.६४
High
€ ५८.१०
Low
€ ५७.६४
Mkt. cap
१.८० खरब
Avg. vol.
१२०.००
Volume
५.००
52-wk high
€ ६१.९६
52-wk low
€ ४६.७४
No. of employees
११ हजार
News stories
From web sources and news partners
Simply Wall Street
·
२२ मिनेट पहिले
Coinbase Stock and 2 Trading Platforms Facing a CFTC Rule Shift
Seeking Alpha
·
१ घण्टा पहिले
15 Years In, I've Never Seen The S&P 500 Hide So Much Damage
Investing.com
·
१८ मिनेट पहिले
Why ’Net Stocks’ are down sharply this year despite Nasdaq’s gains
MarketWatch
·
१ दिन पहिले
S&P 500 at 10,000 or bust: New ETF offers investors all-or-nothing bet on the index
Profile
Novonesis is a biotechnology company headquartered in Lyngby, Denmark. Novonesis was formed in 2024 through the merger of Novozymes and Chr. Hansen.
The company develops enzymes, microbial cultures, and other biological products used in food and beverage production, household products, agriculture, and bioenergy.
The merger, first announced in December 2022, was the largest merger in history between two Danish companies. It would combine Novozymes' industrial-enzyme business with Chr. Hansen's microbial cultures and food-ingredient operations.
The company is publicly traded on Nasdaq Copenhagen and is part of the OMX Copenhagen 25 Index. The company's largest shareholder is Novo Holdings A/S, which is owned by the Novo Nordisk Foundation.
As of 2025, Novonesis has more than 11,000 employees and activities in over 45 countries. Wikipedia
About Novozymes A/S
CEOEster Baiget
Employees११.१ हजार
Founded२०००
Headquarters-
SectorSpeciality chemicals
Websitenovonesis.com